



Cite this: *RSC Adv.*, 2020, 10, 34364

Engineering of NIR fluorescent PEGylated poly(RGD) proteinoid polymers and nanoparticles for drug delivery applications in chicken embryo and mouse models†

Elad Hadad,^a Safra Rudnick-Glick,^a Igor Grinberg,^a Ronen Yehuda^b and Shlomo Margel ^{*a}

Proteinoids are non-toxic biodegradable polymers based on thermal step-growth polymerization of natural or synthetic amino acids. Hollow proteinoid nanoparticles (NPs) may then be formed *via* a self-assembly process of the proteinoid polymers in an aqueous solution. In the present article polymers and NPs based on D-arginine, glycine and L-aspartic acid, poly(R^DGD), were synthesized for tumor targeting, particularly due to the high affinity of the RGD motif to areas of angiogenesis. Near IR fluorescent P(R^DGD) NPs were prepared by encapsulating the fluorescent NIR dye indocyanine green (ICG) within the formed P(R^DGD) NPs. Here, we investigate the effect of the covalent conjugation of polyethylene glycol (PEG), with different molecular weights, to the surface of the near IR encapsulated P(R^DGD) NPs on the release of the dye to human serum due to bio-degradation of the proteinoid NPs and on the uptake by tumors. This work illustrates that the release of the encapsulated ICG from the non-PEGylated NPs is significantly faster than for that observed for the PEGylated NPs, and that the higher molecular weight is the bound PEG spacer the slower is the dye release profile. In addition, in a chicken embryo model, the non-PEGylated ICG-encapsulated P(R^DGD) NPs exhibited a higher uptake in the tumor region in comparison to the PEGylated ICG-encapsulated P(R^DGD) NPs. However, in a tumor xenograft mouse model, which enables a prolonged experiment, the importance of the PEG is clearly noticeable, when a high concentration of PEGylated P(R^DGD) NPs was accumulated in the area of the tumor compared to the non-PEGylated P(R^DGD). Moreover, the length of the PEG chain plays a major role in the ability to target the tumor. Hence, we can conclude that selectivity towards the tumor area of non-PEGylated and the PEGylated ICG-encapsulated P(R^DGD) NPs can be utilized for targeting to areas of angiogenesis, such as in the cases of tumors, wounds or cuts, etc.

Received 11th July 2020
Accepted 26th August 2020

DOI: 10.1039/d0ra06069k

rsc.li/rsc-advances

Introduction

The RGD sequence is a tripeptide composed of three amino acids: arginine (R), glycine (G) and aspartic acid (D). The sequence was initially discovered in 1985 by Pierschbacher and Ruoslahti, to be the active component in fibronectin protein.¹ It has been reported that many cancer cells overexpress the $\alpha v \beta 3$ integrin. This integrin is also highly up-regulated on the surfaces of growing tumor blood vessels. The RGD peptide has a high affinity to the integrin $\alpha v \beta 3$ and is attracted to areas of angiogenesis.^{2–4} These properties of the RGD motif have led to the development of integrin-targeted nano-drugs for imaging

and treatment of tumors. Today, there are two accepted ways for conjugating RGD peptides to nanoparticles (NPs) for targeted drug delivery applications; linear RGD or cyclic RGD peptide.⁵

Amino acids are categorized by L or D configurations which correspond to the ability to rotate polarized light to the left (L) or right (D) directions. It has been reported that the configuration of the amino acids directly influences the RGD peptide activity, which can be reflected in the cell attachment. For example, when the L-aspartic acid is replaced with the D-isomer, the RGD peptide is inactive, however when the L-arginine is replaced by the D-isomer, the binding efficiency increases by a factor of ten.^{6,7}

In this research, proteinoid composed of D-arginine (R), glycine (G), and L-aspartic acid (D) was synthesized, with the intention of randomly achieving the RGD sequence as a part of the proteinoid backbone.

Proteinoids are polymers based on thermal step-growth polymerization which consist of natural or synthetic amino acids. The special procedure was discovered by Fox and

^aDepartment of Chemistry, Institute of Nanotechnology & Advanced Materials, Bar Ilan University, Ramat-Gan, Israel. E-mail: shlomo.margel@biu.ac.il

^bDepartment of Life Science, Bar Ilan University, Ramat-Gan, Israel

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra06069k



Harada.^{8–14} The formation of proteinoids is carried out in the absence of a catalyst or solvent through heating of certain amino acids in an inert atmosphere.^{14–16} The suggested explanation for the polymerization process is that aspartic acid serves as a solvent for the other amino acid monomers, as it is condensed through cyclization upon heating into 2,2'-(3,6-dioxopiperazine-2,5-diyl)diacetic acid, which initiates the polymerization with the rest of the present amino acids, and the proteinoid is formed, as shown in Fig. 1A.¹⁷

The proteinoids are considered to be non-immunogenic (as illustrated in our previous work by cytokines induction assay), biodegradable, and non-toxic.^{17,18} Hence, they serve as a delivery carrier in the human body.

Hollow NPs can be produced by a self-assembly process of the proteinoids in an aqueous solution. The self-assembly process of the proteinoid occurs due to the many functional groups, which are part of the random polymer backbone. When proteinoids precipitate to form particles in an aqueous solution, the hydrophobic residues (*e.g.*, phenyl groups) form a hydrophobic core inside the particle, in order to minimize their contact with water. While the carboxylic groups (or ammonium ions when dealing with a lysine-rich proteinoid) will form hydrogen bonds and reside on the particle surface.

We propose a novel R^DGD based proteinoid NPs, where there R^DGD motif is self-incorporated in the proteinoids' backbone. The superscript letters correspond to the configuration of the arginine and the aspartic acid in all cases. ICG encapsulation towards these NPs act both as a drug carrier (by encapsulation of a desired drug) cell labeling and as a targeting delivery system. This work offers a fast and cheap method for the

synthesis of R^DGD based proteinoid NPs which can be suitable for biomedical imaging and diagnostics. In order to improve the bio-stability of the ICG encapsulated NPs, the NPs were PEGylated. The self-assembly and formation of the PEGylated ICG-encapsulated P(R^DGD) NPs is demonstrated in Fig. 1B–D.

Although recent studies exhibit that PEGylated drugs can cause the formation of antibodies which specifically recognize and bind to polyethylene glycol (PEG),¹⁹ PEGylation to NPs still have a major role in drug delivery systems such as: increase in blood circulation,²⁰ evading phagocytosis,²¹ enhance serum stability²² which is critical for biological application, and prevents leakage of the dyes or drugs.²³

Materials and methods

Materials

The following chemicals were purchased from Sigma and used without further purification: D-arginine, glycine, L-aspartic acid, NaCl, Hoechst (bisbenzimidazole H33342 trihydrochloride) and indocyanine green (ICG). NHS-PEG, *M_w* 750. NHS-PEG, *M_w* 5000. HUVEC cells and their EBM-2 medium were purchased from Lonza. PBS and XTT kit were ordered from Biological Industries.

Synthesis of the P(R^DGD) proteinoids by step-growth polymerization mechanism

In order to determine if the addition of PEG has a role in the stabilization of the P(R^DGD) NPs a mixture of 5 g total of amino acids was heated in a three-neck flask by a heating mantle to 180 °C, under nitrogen atmosphere, until all the solid dissolved.




Fig. 1 Illustration of the thermal step-growth polymerization of amino acids through aspartic cyclization catalysis (A), PEGylated ICG-encapsulated P(R^DGD) NPs formation as follows: a crude P(R^DGD) proteinoid (B), encapsulation of ICG molecules (green spheres) during the self-assembly of the P(R^DGD) to form an ICG-encapsulated P(RGD)NPs (C), PEGylation of NHS-PEG (*M_w* 750 or 5000) through conjugation of NHS-ester groups to the ICG-encapsulated P(R^DGD)NPs (D).



The mixture was stirred by a mechanical stirrer at 250 rpm for 20 min, producing a highly viscous yellowish to brownish paste. The paste was allowed to cool to room temperature and harden to a glassy mass was formed. After cooling, the residue was extracted by 30 ml of distilled water, and lyophilized to yield the crude proteinoid.

Proteinoid analysis and characterization

The molecular weight and polydispersity index of the P(R^DGD) was determined by Gel Permeation Chromatography (GPC) consisting of a Waters Spectra Series P100 isocratic HPLC pump with ERMA ERC-7510 refractive index detector and Rheodyne injection valve (Cotati, CA) with a 20 μ l loop (Waters, MA). The sample was dissolved with super-pure HPLC water (Sigma) through linear BioSep SEC-s3000 column (Phenomenex) at a flow rate of 1 ml min⁻¹. The molecular weight of the proteinoids was determined relative to bovine plasma fibrinogen (340 kDa), and human serum albumin (67 kDa), using Clarity chromatography software.

The absorption spectra of the proteinoid was obtained by using a Cary 100 UV-Visible (UV-Vis) spectrophotometer (Agilent Technologies Inc.). All of the measurement was performed in water at 25 °C. Excitation and emission spectra were recorded using a Cary Eclipse spectrophotometer (Agilent Technologies Inc.).

Preparation and characterization of hollow, NIR fluorescent proteinoid P(R^DGD) nanoparticles

NIR fluorescent P(R^DGD) NPs were prepared by a self-assembly process. Briefly, 50 mg of dried proteinoids were added to 5 ml of 10⁻⁵ M NaCl aqueous solution. The mixture was then stirred at 250 rpm and heated to 80 °C until the proteinoid dissolved completely. 0.5 mg of ICG (1% relative to the proteinoid weight) was dissolved in 0.1 ml of 10⁻⁵ M NaCl aqueous solution. After 30 min of heating, 0.1 ml of the ICG solution was added to the proteinoid mixture. The mixture was then left to cool slowly to room temperature, in order to form the ICG-encapsulated proteinoid NPs.

PEGylation of ICG-encapsulated proteinoid NPs

PEGylated ICG-encapsulated P(R^DGD) NPs were prepared by coupling free primary amine groups of the P(R^DGD) NPs with the NHS-PEG (M_w 750). Briefly, water (100 μ l) and PBS buffer (200 μ l) were added to 2 ml of ICG-encapsulated P(R^DGD) NPs (10 mg ml⁻¹ in water). NHS-PEG (M_w 750, 1 mg) was dissolved in water (100 μ l) and 50 μ l of the NHS-PEG solution was added to the ICG-encapsulated P(R^DGD) NPs to obtain the PEGylated ICG-encapsulated P(R^DGD) NPs. The reaction was stirred for 1 h at room temperature. Then, the obtained PEGylated ICG-encapsulated P(R^DGD) NPs were washed from excess of PEG in dialysis cellulose membrane (~12 kDa MWCO) against super-purified water. NHS-PEG, M_w 5000 was conjugated in a similar manner. The hydrodynamic and the dry diameters and size distribution of the NPs were characterized by DLS (Vasco 2, Cordouan Technologies SAS, France) and high resolution scanning electron microscopy (HR-SEM).

We refer to the PEGylated (M_w 750) ICG-encapsulated P(R^DGD) and PEGylated (M_w 5000) ICG-encapsulated P(R^DGD) RGD NPs as PEGylated (750) ICG-encapsulated P(R^DGD) and PEGylated (500) ICG-encapsulated P(R^DGD) NPs throughout this manuscript, respectively.

Stability of the P(R^DGD) NPs in wet and dry states

Stability of the non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs was checked in both wet and dry states. In the wet state, PBS dispersions of the various P(R^DGD) NPs (10 mg ml⁻¹) were kept at 4 °C for 1 month while following their diameter. In the dry state, 10 mg of trehalose were added to 1 ml NP aqueous dispersions (10 mg ml⁻¹) followed by lyophilization and then storage at 4 °C. The NP powders were then redispersed in water to their original concentration, then were characterized for their diameter.

ICG loading capacity

Calibration curve of free ICG was obtained by measuring the mean excitation peaks intensity of standard solutions (0.5–10 μ g ml⁻¹) in water, at wavelength of 700–900 nm. The concentration of the ICG within the fluorescent PEGylated P(R^DGD) and the non-PEGylated P(R^DGD) NPs was determined by measuring the fluorescence intensity of the excitation peaks of the corresponding absorbance of a 10–0.1 mg ml⁻¹ dispersion of free ICG in water. An estimation of encapsulated material per mg of NPs was determined according to the calibration curve.

Photostability of the encapsulated ICG

An aqueous solution of free ICG, ICG encapsulated PEGylated P(R^DGD) and the non-PEGylated P(R^DGD) NPs in water were prepared to give similar fluorescence intensity. The fluorescence intensities were measured with λ_{ex} set at 780 nm and λ_{em} set at 800 nm for ICG. Each of the samples was illuminated continuously with a xenon lamp, and the fluorescence intensity was measured over a period of 30 min by a Synergy fluorescence spectrophotometer (Agilent Technologies Inc.). Intensity values were normalized for comparison.

Drug release model

PEGylated (M_w 750 and 5000) P(R^DGD) and non-PEGylated ICG-encapsulated P(R^DGD) NPs (500 μ l, 10 mg ml⁻¹) were incubated with PBS buffer (4.5 ml) or human serum (500 μ l) and PBS buffer (4 ml), at 37 °C, giving a final concentration of 1 mg ml⁻¹ NPs in a total volume of 5 ml. Samples were collected at several periods of time and the released ICG, as a model, was measured by UV spectrophotometer.

In vitro XTT cell viability assay

The XTT assay was performed to determine the viability of the mCherry-labeled 4T1 mammary carcinoma cells after treatment with PEGylated and non-PEGylated ICG-encapsulated P(R^DGD) NPs. Cells were seeded in a 96 well plate at a density of 10⁴ cells per well in 100 μ l culture medium and grown in a humidified 5% CO₂ atmosphere at 37 °C. After 48 h



at 37 °C, different volumes of the proteinoid NPs dispersed in water were added to the cells, giving final concentrations of 1 mg per ml per well. After incubation for 48 h at 37 °C, 50 µl XTT solution was added to each well according to the kit manufacturer's instructions. Absorbance was read at 490 nm. Cell viability was determined using the formula shown in the manufacturer's protocol.

Chicken embryo model

Fertile chicken eggs were incubated in a forced-draft incubator at a temperature of 37 °C and humidified about 60% for 8 days, as described in the literature.^{24,25} Chorioallantoic membrane (CAM) was exposed, as a window was opened in the egg-shell after 8 days of incubation. 30 µl Matrigel was mixed with 5×10^6 4T1-RFP cells and implanted in the egg's CAM on a plastic ring. After 13 days, 100 µl of 0.1 mg ml⁻¹ of the 3 different aqueous dispersed particles: PEGylated (5000) ICG-encapsulated P(R^DGD), PEGylated (750) ICG-encapsulated P(R^DGD) and non-PEGylated ICG-encapsulated P(R^DGD) NPs were injected Intravenously (IV) into the largest blood vessels of each egg. After the injection, the window in the shell was sealed with transparent sellotape, and the chicken embryos were incubated and sacrificed after 4 h and 24 h post injection. Each experiment group contained 6 chicken embryos. The tumors of each embryo was examined in the MAESTRO fluorescence *in vivo* imaging system. Comparison of the tumors was performed by scanning the tumors at two wavelengths (fluorescent intensity of particles relative to fluorescent intensity of cancer cells).

Non-PEGylated and PEGylated P(R^DGD) NPs performance towards mCherry-labeled 4T1 breast tumors in Balb/c mouse model

Female Balb/c mice (8 week old, Harlan Laboratories, Inc. Israel) were injected intra-flank with 5×10^5 mCherry-labeled 4T1 cells suspended in Matrigel. One week post injection the tumor appeared, and the mice were divided into 4 groups ($n = 4$) and were IV injected into the tail vein with 100 µl of free ICG (0.1 mg ml⁻¹), PEGylated (750) ICG-encapsulated P(R^DGD) NPs, PEGylated (5000) ICG-encapsulated P(R^DGD) NPs and non-PEGylated ICG-encapsulated P(R^DGD) NPs. The mice were sacrificed and their organs were scanned after 1, 2 and 5 days post treatment, using Maestro *in vivo* imaging system. Cy7 filter: λ_{ex} 710–760 nm, $\lambda_{\text{em}} > 800$ nm was used to image the ICG and Cy5 filter was used to image the mCherry expressing tumor filter for the NPs. This experiment was repeated 3 times, while each experiment consisted of 4 mice per group.

Animal experiments

All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Bar-Ilan University and approved by the Animal Ethics Committee of Bar Ilan University.

Results and discussion

Synthesis and characterization of the R^DGD proteinoid

The RGD proteinoid was synthesized while the aspartic acid serves as part of the RGD building blocks as well as a solvent and linker which helps to reduce the polymerization energy.¹⁶ Commonly, in our previous preparations a glassy mass was formed following proteinoid polymerization synthesis, and the water-soluble proteinoid polymer was separated from the insoluble cross-linked proteinoid polymer mass. In comparison to previously published proteinoids, no cross-linked proteinoid was obtained and the water-soluble P(RGD) yield was 100%. Table 1 exhibits the molecular weight and polydispersity indices (PDI) of the obtained P(R^DGD). The relative high molecular weights (67 660 Da) and very narrow molecular weight mono-dispersity is not expected but fits to our previous publications,^{17,26,27} since commonly step-growth polymerization

Table 1 M_w , M_n , M_p and polydispersity indices of the proteinoid

Polymer	M_w^a (Da)	M_n^b (Da)	M_p^c (Da)	PDI ^d
P(R ^D GD)	67 660	67 640	66 465	1.0003

^a Weight average molecular weight (M_w). ^b Number average molecular weight (M_n). ^c Molecular weight at the peak (M_p). ^d PDI is the polydispersity index.




Fig. 2 FTIR spectrum (A) and UV-Vis absorption spectra (B) of P(R^DGD).



Table 2 Dry diameter (nm), hydrodynamic diameter (nm) and zeta potential (mV) of the P(R^DGD) NPs

NPs series	Dry diameter ^a (nm)	Hydrodynamic diameter ^b (nm)	Zeta potential ^c (mV)
ICG-encapsulated P(R ^D GD)	95 ± 13	93 ± 20	−30 ± 7
PEGylated (750) ICG-encapsulated P(R ^D GD)	93 ± 15	177 ± 30	5 ± 3
PEGylated (5000) ICG-encapsulated P(R ^D GD)	95 ± 15	216 ± 25	3 ± 1

^a Dry diameters (nm) were analyzed by using ImageJ software, an open source Java image processing program, as described in the Materials and methods section. ^b Wet diameters (nm) were measured by DLS. ^c Zeta potentials were measured by zetasizer zeta potential analyzer.

processes result in low molecular weight polymers with broad molecular weight polydispersity.²⁸

The P(R^DGD) proteinoid was characterized by FTIR spectrometer and UV-Vis spectroscopy. This proteinoid showed similar peaks of NH stretching at 3356 and 2951 cm^{−1}, amide CO stretching at 1570 cm^{−1}, an amide NH bending band at 1490 cm^{−1} and CO bending at 500–660 cm^{−1}, as shown in Fig. 2A. A characteristic absorbance peak was observed for the P(R^DGD) proteinoid at 218 nm reflecting the absorbance of the peptide bonds, as shown in Fig. 2B.²⁹

The P(R^DGD) polymer contains one primary amine group, through which the NHS-PEG was bound (Fig. 1), at the terminal of each polymeric chain. Since the molecular weight of this polymer is 67 600 g mol^{−1} we may calculate the concentration of the primary amine groups to be approximately 10^{−2} mmol g^{−1} proteinoid.

Non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs characterization

Encapsulation of the near IR dye, ICG, within P(R^DGD) NPs was produced during the self-assembly process of the proteinoid NPs. The dry diameter of the ICG encapsulated NPs compared to the hollow NPs increased to 95 ± 13 nm from 47 ± 9, respectively, indicating a successful encapsulation of ICG.³⁰

The hydrodynamic size of the ICG-encapsulated NPs was 93 ± 20 nm. Following PEGylation of the ICG-encapsulated P(R^DGD) NPs with NHS-PEG, *M_w* 750 or 5000, the hydrodynamic diameter increased to 177 ± 30 and 216 ± 25, respectively (Fig. 3).

In contrast, the dry diameter did not change significantly (Table 2). Rahme, K. *et al.* reported that the differences in layer thickness in the range of PEG (*M_w* 750–5000) is ~0.4² nm, hence no great change in NPs diameter is noticed.³¹

Zeta potential (ζ-potential) measurement at pH 11 demonstrated a change from −30 mV for the ICG-encapsulated P(R^DGD) NPs to 5 and 3 mV for the PEGylated P(R^DGD) NPs with the *M_w* 750 or 5000, respectively. The negative charge measured was due to the carboxyl residue on the particles surface. The decrease in the ζ-potential may indicate a successful conjugation of the PEG chains to the surface residues of the P(R^DGD) NPs.^{31,32}

The concentration of the encapsulated ICG was determined according to the calibration curve of the free ICG in water, at wavelength of 700–900 nm. The concentration of the encapsulated ICG was calculated to be 0.1 mg ml^{−1} per 10 mg NPs (1%

w/w ICG relative to the proteinoid NPs). The stability of the dispersed NPs in an aqueous phase (10 mg ml^{−1}, stored at 4 °C) against agglomeration was evaluated over a period of 1 month. No change in the non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs diameter was observed (see Fig. S1 and Table S1†). The stability of these NPs in the dry state was investigated by adding 10 mg of trehalose (a well-known cryoprotectant routinely used for this purpose)³³ to 1 ml NP aqueous dispersion (10 mg ml^{−1}) followed by lyophilization and then storage at 4 °C for 1 month. The NP powders were then redispersed in water to their original concentration, and found to have the same diameter and size distribution, indicating their stability against agglomeration.

Photostability of the encapsulate ICG

It has been reported that encapsulation of a fluorophore can increase the photostability of dye fluorescence degradation.³⁴ Illumination was performed continuously at 780 nm for




Fig. 3 Size distributions measured by the DLS and SEM micrograph of PEGylated (5000) ICG-encapsulated P(R^DGD) NPs (A and D), PEGylated (750) ICG-encapsulated P(R^DGD) NPs (B and E), and non-PEGylated of ICG-encapsulated P(R^DGD) NPs (C and F).



a period of 30 minutes, for the non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs and were compared to the photostability of the free ICG. While the fluorescence intensity of the non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs was not affected by the continuous illumination, the free ICG fluorescence decreased by 20%, as shown in Fig. 4. This indicates that ICG is encapsulated within the NPs and thus is protected against oxidation, reducing agents, heat, illumination levels or exposure time which may decrease the fluorescence intensity.^{35,36}

Controlled release of ICG from the non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs in PBS and human serum

A common method for studying the *in vitro* drug release is by incubation in human serum or PBS.³⁷ In order to evaluate the ICG (a drug model) release from the non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs in different physiological conditions, the NPs were incubated in PBS or human serum for 2.5 h at 37 °C. Fig. 5 demonstrates the UV absorbance intensities of ICG from the non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs following treatment in human serum (Fig. 5A) or PBS (Fig. 5B). The sustained release of the ICG from the non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs in human serum is probably due to the degradation of the P(R^DGD) NPs which are biodegradable by proteolytic enzymes in the serum.¹⁶ It is clearly evident that following 2.5 h incubation in human serum, the non-PEGylated ICG-encapsulated P(R^DGD) NPs absorbance significantly decreases by 40%. On the other hand, there is a significantly less decrease by 10 and 20% in the absorbance of the *M_w* 5000 and 750 PEGylated ICG-encapsulated P(R^DGD) NPs, respectively. The difference in the ICG degradation of the NPs could be explained by the presence of the PEG chains and the importance of the chains length in preventing the NPs biodegradation.³⁸ Hence, it can be deduced that the longer the PEG chain, the stability of the ICG within the NPs increases. On the other hand, following incubation with PBS, a slight, but not significant, decrease of 5% in UV absorbance is noticeable in all samples. To




Fig. 4 Photostability of the PEGylated and non-PEGylated ICG-encapsulated and free ICG. ICG-encapsulated (5000) P(R^DGD) NPs (red line), ICG-encapsulated P(R^DGD) NPs (blue line), ICG-encapsulated (750) P(R^DGD) NPs (green line), black free ICG and free ICG (black line) as function of time.




Fig. 5 Relative absorbance of non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs in various physiological solutions: human serum (A) and PBS (B) over 2.5 h incubated at 37 °C.

summarize, the results indicated a successful PEG conjugation, and it clearly demonstrates that PEGylation has major influence on the release rate of the ICG from the P(R^DGD) NPs to the continuous phase.

Cytotoxicity of the P(R^DGD) NPs for 4T1 mammary carcinoma cells

mCherry-labeled 4T1 mammary carcinoma cells were treated for 48 h with ICG-encapsulated non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs (1 mg ml⁻¹). Fig. 6 exhibits the cell viability levels post treatment. Cells treated with non-




Fig. 6 Cell viability levels of mCherry-labeled 4T1 mammary carcinoma cells after exposure to non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs (1 mg ml⁻¹) measured by XTT assay. Cells (10⁴) were incubated for 48 h with NPs dispersed in PBS, in accordance with the Experimental section. Untreated cells (positive control) were similarly incubated. Each bar represents the mean \pm standard deviations of 6 separate samples.



PEGylated and the PEGylated P(R^DGD) did not exhibit any decrease in the cell viability after 48 h of treatment. It should be noted that the cell viability increases (above 100%) after 48 hours of treatment, this could be explained by the uptake of the P(RGD) NPs as a nutrient (*e.g.*, glucose, amino acids *etc.*).³⁹ In conclusion, both the non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs do not exhibit any toxic effect towards the cells.

Non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs targeting of mCherry-labeled 4T1 tumor in a CAM model

The chick chorioallantoic membrane (CAM) experiment is a well-known model, simple and of low cost in comparison to other animal models. The advantage of this model is reduction of unnecessary animal suffering since the procedure is carried out on the embryonic tissue. In addition, the membrane located around the chicken embryo can be utilized to graft tumor explants as its highly vascularized,^{24,40} and thus it enables to carry out *in vivo* studies of tumors in a short period of time and reduce the number of mice in further experiments. The fertile chicken eggs were incubated in a forced-draft incubator and a chorioallantoic membrane (CAM) was exposed, as a window and 4T1-RFP cells that were implanted begin to grow into a solid tumor on a plastic ring as shown in Fig. 7A. The PEGylated (750 or 5000) ICG-encapsulated P(R^DGD) and the ICG-encapsulated P(R^DGD) NPs were injected Intravenously (IV) into the largest blood vessels of each egg, as demonstrated in Fig. 7B. Fig. 7C demonstrates 4T1 mammary carcinoma tumors explants on the CAM following treatment with non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs after 4 and 24 h. Both the P(R^DGD) NPs, the PEGylated and the non-PEGylated, reached to the tumor. The fluorescence intensity of non-PEGylated ICG-encapsulated P(R^DGD) NPs was significantly higher in comparison to the PEGylated ICG-encapsulated NPs. Indicating that non-PEGylated ICG-encapsulated P(R^DGD)

NPs accumulated with higher concentration after 4 and 24 h compared to the PEGylated ICG-encapsulated P(R^DGD) NPs. This fact can be explained due to the PEGylation of the P(R^DGD) NPs that yields an improved packing with lesser bio-degradable bonds which prevent a quick disassembly of the PEGylated P(R^DGD) NPs at the tumor site, resulting a decrease rate of ICG release.

Non-PEGylated and PEGylated ICG-encapsulated P(R^DGD) NPs targeting in a mice model treated with mCherry-labeled 4T1 mammary carcinoma cells

In order to evaluate the performance of the PEGylated and the non-PEGylated ICG-encapsulated P(R^DGD) NPs towards tumor for prolonged time, more than 24 h, an experiment in *in vivo* xenograph mouse model was performed. Mice cancer 4T1 mammary carcinoma cells were injected subcutaneously into Balb/c mice to induce a xenograft. Two weeks after the tumor injection the mice were treated with free ICG 0.1 $\mu\text{g ml}^{-1}$ or 100 μl of 0.1 mg ml^{-1} of either non-PEGylated or PEGylated ICG-encapsulated P(R^DGD) NPs *via* IV injection into the tail vein. The fluorescence intensity measurements prior injection of the free ICG and the non-PEGylated or PEGylated ICG-encapsulated P(R^DGD) NPs were all equal. Analysis of the fluorescence intensity images of tumors which were harvested after 24, 48, and 120 h post injection is demonstrated in Fig. 8. It is clearly noticeable that, as time progresses the fluorescence of the PEGylated and the non-PEGylated ICG-encapsulated P(R^DGD) NPs and still remains visible. These results clearly indicated that PEGylated and non-PEGylated ICG-encapsulated P(R^DGD) NPs accumulate in the area of the tumor as time passes after 24, 48 and 120 h indicating a targeted delivery of the NPs to the tumor and not a passive uptake as demonstrated in Fig. 8A–C. The fluorescence intensities of the free ICG a decreased rapidly and didn't present after 24 and 48 h in the tumor areas as shown in Fig. 8D, respectively. Furthermore, unlike the PEGylated ICG-




Fig. 7 Top view of the inner tumor on the CAM (white arrow) (A), and the IV injection of P(R^DGD) NPs in a CAM model (white arrow) (B). Fluorescent intensity analysis from experiment of 4T1 mammary carcinoma tumor cells implanted on CAM treated with non-PEGylated and the PEGylated ICG encapsulated P(R^DGD) NPs and untreated 4T1 mammary carcinoma tumor cells 4 and 24 h post injection (C).






Fig. 8 Shows the fluorescence and bright field images uptake of the PEGylated 5000 (I) and 750 (II) and the non-PEGylated ICG-encapsulated P(R^DGD) NPs (III) toward 4T1 mammary carcinoma tumors after (A) 24, (B) 48 and (C) 120 h, and free ICG (IV) after (D) 24, 48 h. The fluorescence intensities analysis of the tumors after the treatment of the PEGylated and the non-PEGylated ICG-encapsulated P(R^DGD) NPs (E).

encapsulated P(R^DGD) NPs which the fluorescence increased with time, the ICG-encapsulated P(R^DGD) NPs did not change significantly and remained relatively stable (Fig. 8E). Hence it can be concluded that the addition of the PEG has a major role in the stabilization of the particle. In addition, the results also indicate that the length of the PEG chain has an effect on the targeting ability of the NPs. The elongation of the PEG from M_w 750 to 5000 directly reduces the PEGylated ICG-encapsulated P(R^DGD) NPs migration towards the tumors, indicating enhanced PEG shielding.⁴¹ After 120 h the ICG-encapsulated (750) P(R^DGD) NPs exhibited to be the most efficient compared to the other particles. Recent studies^{42,43} suggested that NPs which are not charged and have a small hydrodynamic diameter, can be an ideal candidate for targeted cancer delivery, due to reduced cellular interactions such as, interactions with healthy human cells. The ICG-encapsulated (750) P(R^DGD) NPs (177 ± 30 nm) confirmed this study, as on the one hand they are not as large as the ICG-encapsulated (5000) P(R^DGD) NPs (216 ± 25 nm) and on the other hand they are not significantly charged (5 ± 3 mV) as the ICG-encapsulated P(R^DGD) NPs (-30 ± 7 mV).

Summary and conclusions

In this study, we present low cost and simple proteinoids nanoparticles based on amino acid arginine (P), glycine and aspartic acid as building block. The self-assembly of the P(R^DGD) proteinoid to in the presence of ICG yielded ICG-encapsulated P(R^DGD) NPs. PEGylation of ICG-encapsulated P(R^DGD) NPs were produced with conjugating NHS-PEG, with different PEG lengths (M_w 750 and 5000), yielding ICG-encapsulated (750 or 5000) P(R^DGD) NPs. All the PEGylated and the non-PEGylated ICG-encapsulated P(R^DGD) NPs prove to be a successful encapsulation for ICG. Photostability tests demonstrated that following ICG encapsulation and PEGylation of the P(R^DGD) NPs, the fluorescence of the encapsulated-ICG was stable in comparison to the free ICG. The PEGylated and the non-PEGylated ICG-encapsulated P(R^DGD) NPs exhibited similar dry diameter of ~ 95 nm. However, the hydrodynamic

size was different 93 ± 20 nm for the non-PEGylated ICG-encapsulated P(R^DGD) NPs and 177 ± 30 and 216 ± 25 nm for the PEGylated ICG-encapsulated P(R^DGD) NPs (750 or 5000). All of the P(R^DGD) NPs exhibit no cytotoxicity towards 4T1 mammary carcinoma cells. In human serum stability tests the P(R^DGD) with the longer PEG chain (M_w 5000) demonstrated better stability than the shorter PEG chain (M_w 750) or the non-PEGylated. In CAM model, the ICG-encapsulated P(R^DGD) NPs exhibited a higher uptake in the tumors region in comparison to the PEGylated ICG-encapsulated P(R^DGD) NPs. However, in tumor xenograft mouse model, which enables to prolonging of the experiment, it is clearly noticeable the importance of the PEG due to the high accumulation with time of both the PEGylated P(R^DGD) NPs compared to the non-PEGylated P(R^DGD). Moreover, the length of the PEG chain plays a major role in the ability to target the tumor. The longer the PEG chain, the NPs the RGD residues on the NPs are more shielded and the targeted ability of the NPs are reduced. Hence, we can conclude that selectivity towards the tumors area of PEGylated and the non-PEGylated ICG-encapsulated P(R^DGD) NPs can be utilized for targeting to areas of angiogenesis, such as in the cases of tumors, wounds or cuts, *etc.*

Our future plans include investigating the ability of P(R^DGD) NPs as a targeted drug carrier by encapsulating and conjugating various chemotherapeutics such as doxorubicin or paclitaxel or other proteins to the R^DGD proteinoid NPs.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

There are no conflicts to declare.

References

- 1 M. D. Pierschbacher and E. Ruoslahti, *Nature*, 1984, **309**, 30–33.



- 2 P. K. Dubey, V. Mishra, S. Jain, S. Mahor and S. P. Vyas, *J. Drug Targeting*, 2004, **12**, 257–264.
- 3 S. M. Weis and D. A. Cheresch, *Nat. Med.*, 2011, **17**, 1359–1370.
- 4 X. Fu, Y. Yang, X. Li, H. Lai, Y. Huang, L. He, W. Zheng and T. Chen, *Nanomedicine*, 2016, **12**, 1627–1639.
- 5 H. Q. Yin, D. S. Mai, F. Gan and X. J. Chen, *RSC Adv.*, 2014, **4**, 9078–9085.
- 6 E. Ruoslahti, *Annu. Rev. Cell Dev. Biol.*, 1996, **12**, 697–715.
- 7 B. Kieffer, G. Mer, A. Mann and J.-F. Lefèvre, *Int. J. Pept. Protein Res.*, 2009, **44**, 70–79.
- 8 S. W. Fox, *Science*, 1960, **132**, 200–208.
- 9 S. W. Fox, *Am. Biol. Teach.*, 1974, **36**, 161–172.
- 10 S. W. Fox, *Geochim. Cosmochim. Acta*, 1995, **59**, 1213–1214.
- 11 S. W. Fox, J. R. Jungck and T. Nakashima, *Origins Life*, 1974, **5**, 227–237.
- 12 P. O. Montgome, S. W. Fox, R. J. Mccauley, T. Fukushima and C. R. Windsor, *Fed. Proc.*, 1967, **26**, 749.
- 13 R. M. Syren, S. W. Fox, T. Nakashima and A. Przybylski, *Int. J. Nanomed.*, 1982, **22**, 195–204.
- 14 S. W. Fox and K. Harada, *US Pat.*, 3052655, 1962.
- 15 K. Harada and M. Matsuyama, *BioSystems*, 1979, **11**, 47–53.
- 16 M. Kolitz-Domb and S. Margel, *Isr. J. Chem.*, 2018, **58**, 1277–1285.
- 17 S. M. S. Kile, M. Kolitz-Domb and E. Corem-Salkmon, *International Journal of Nanotechnology and Nanomedicine*, 2017, **2**, 1–11.
- 18 A. Madhan Kumar and K. Panduranga Rao, *Biomaterials*, 1998, **19**, 725–732.
- 19 T. T. H. Thi, E. H. Pilkington, D. H. Nguyen, J. S. Lee, K. D. Park and N. P. Truong, *Polymers*, 2020, **12**(2), 298–319.
- 20 K. Kazunori, S. K. Glenn, Y. Masayuki, O. Teruo and S. Yasuhisa, *J. Controlled Release*, 1993, **24**, 119–132.
- 21 P. Aggarwal, J. B. Hall, C. B. McLeland, M. A. Dobrovolskaia and S. E. McNeil, *Adv. Drug Delivery Rev.*, 2009, **61**, 428–437.
- 22 C. Peng, L. Zheng, Q. Chen, M. Shen, R. Guo, H. Wang, X. Cao, G. Zhang and X. Shi, *Biomaterials*, 2012, **33**, 1107–1119.
- 23 A. Gabizon and F. Martin, *Drugs*, 1997, **54**(suppl. 4), 15–21.
- 24 A. Vargas, M. Zeisser-Labouèbe, N. Lange, R. Gurny and F. Delie, *Adv. Drug Delivery Rev.*, 2007, **59**, 1162–1176.
- 25 N. A. Lokman, A. S. F. Elder, C. Ricciardelli and M. K. Oehler, *Int. J. Mol. Sci.*, 2012, **13**, 9959–9970.
- 26 E. Sason, M. Kolitz-Domb, J. H. Chill and S. Margel, *ACS Omega*, 2019, **4**, 9352–9360.
- 27 M. Kolitz-Domb and S. Margel, *Isr. J. Chem.*, 2018, **58**, 1277–1285.
- 28 A. Yokoyama and T. Yokozawa, *Macromolecules*, 2007, **40**, 4093–4101.
- 29 J. M. Walker, *The Protein Protocols Handbook*, 1996.
- 30 S.-J. J. Kim, P. K. Bae and B. H. Chung, *Chem. Commun.*, 2015, **51**, 107–110.
- 31 K. Rahme, L. Chen, R. G. Hobbs, M. A. Morris, C. O'Driscoll and J. D. Holmes, *RSC Adv.*, 2013, **3**, 6085–6094.
- 32 B. Pelaz, P. Del Pino, P. Maffre, R. Hartmann, M. Gallego, S. Rivera-Fernández, J. M. De La Fuente, G. U. Nienhaus and W. J. Parak, *ACS Nano*, 2015, **9**, 6996–7008.
- 33 Y. Gokce, B. Cengiz, N. Yildiz, A. Calimli and Z. Aktas, *Colloids Surf., A*, 2014, **462**, 75–81.
- 34 S. Cohen, M. Pellach, Y. Kam, I. Grinberg, E. Corem-Salkmon, A. Rubinstein and S. Margel, *Mater. Sci. Eng., C*, 2013, **33**, 923–931.
- 35 P. Sharma, S. Brown, G. Walter, S. Santra and B. Moudgil, *Adv. Colloid Interface Sci.*, 2006, **123–126**, 471–485.
- 36 E. I. Altinoğlu and J. H. Adair, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2010, **2**, 461–477.
- 37 T. H. Kim, Y. Chen, C. W. Mount, W. R. Gombotz, X. Li and S. H. Pun, *Pharm. Res.*, 2010, **27**, 1900–1913.
- 38 S. T. Proulx, P. Luciani, S. Derzsi, M. Rinderknecht, V. Mumprecht, J. C. Leroux and M. Detmar, *Cancer Res.*, 2010, **70**, 7053–7062.
- 39 M. G. Vander Heiden, L. C. Cantley, C. B. Thompson, P. Mammalian, C. Exhibit and A. Metabolism, *Sci.* **80**, 2009, **324**, 1029.
- 40 F. Durupt, D. Koppers-Lalic, B. Balme, L. Budel, O. Terrier, B. Lina, L. Thomas, R. C. Hoeben and M. Rosa-Calatrava, *Cancer Gene Ther.*, 2012, **19**, 58–68.
- 41 Z. Ge, Q. Chen, K. Osada, X. Liu, T. A. Tockary, S. Uchida, A. Dirisala, T. Ishii, T. Nomoto, K. Toh, Y. Matsumoto, M. Oba, M. R. Kano, K. Itaka and K. Kataoka, *Biomaterials*, 2014, **35**, 3416–3426.
- 42 S. Y. Khor, M. N. Vu, E. H. Pilkington, A. P. R. Johnston, M. R. Whittaker, J. F. Quinn, N. P. Truong and T. P. Davis, *Small*, 2018, **14**, 1–13.
- 43 M. N. Vu, H. G. Kelly, A. K. Wheatley, S. Peng, E. H. Pilkington, N. A. Veldhuis, T. P. Davis, S. J. Kent and N. P. Truong, *Small*, 2020, 2002861.

